Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)

This study tests whether a drug called abiraterone at a lower dose (250 mg, instead of the standard 1000 mg) can lower testosterone enough to treat prostate cancer without needing the usual hormone-blocking injections (LHRH analogs). **You may be eligible if...** - You are 18 or older - You have confirmed prostate cancer - You are being treated at Hospital Durand (Argentina) or Instituto Oncológico del Oriente Boliviano (Bolivia) - Your doctor has determined you need hormonal intensification (e.g., high/very-high risk candidates for radiation, or cancer that has spread) - You have not previously received hormone deprivation therapy (ADT) - You are in good health (ECOG 0-2) with adequate organ function **You may NOT be eligible if...** - You have already received hormone therapy for prostate cancer - You have serious liver problems or low potassium levels - You have uncontrolled high blood pressure - You have had a prior heart attack or serious heart disease Talk to your doctor to see if this trial is right for you.